VCP→TDP-43→ALS/FTD Causal Chain

📖 Wiki Page

mechanism2601 wordssynced 2026-04-02

VCP→TDP-43→ALS/FTD Causal Chain

Overview

This page traces the complete causal chain from [VCP](/genes/vcp) gene mutations through [TDP-43](/proteins/tdp-43-protein) protein aggregation to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). VCP mutations cause a unique multisystem proteinopathy with overlapping features of ALS, FTD, inclusion body myopathy, and Paget disease of bone.

Gene Summary: VCP

Gene Overview

| Property | Value |
|----------|-------|
| Gene Symbol | VCP |
| Chromosome | 9p13.3 |
| Protein | Valosin Containing Protein (p97) |
| Function | AAA+ ATPase, protein quality control |
| Inheritance | Autosomal dominant |

Structure

VCP/p97 is a 806-amino acid AAA+ ATPase with a modular architecture:

flowchart TD A["VCP Protein (806 aa)"] A --> B["N-terminal domain (N)"] B --> C["D1 ATPase domain"] C --> D["D2 ATPase domain"] D --> E["C-terminal domain"]

N-terminal domain: Adapter protein binding, substrate recognition
D1 domain: First ATPase domain, hexamer assembly
D2 domain: Second ATPase domain, major catalytic activity
C-terminal domain: Regulatory, substrate interaction

VCP forms a hexameric ring that uses ATP hydrolysis to extract ubiquitinated substrates from membranes or protein complexes.

VCP Variants in Neurodegeneration

Over 50 pathogenic variants have been identified in VCP[@watts2004]:

...

VCP→TDP-43→ALS/FTD Causal Chain

Overview

Gene Summary: VCP

Gene Overview

Structure

VCP/p97 is a 806-amino acid AAA+ ATPase with a modular architecture:

Mermaid diagram (expand to render)

N-terminal domain: Adapter protein binding, substrate recognition
D1 domain: First ATPase domain, hexamer assembly
D2 domain: Second ATPase domain, major catalytic activity
C-terminal domain: Regulatory, substrate interaction

VCP forms a hexameric ring that uses ATP hydrolysis to extract ubiquitinated substrates from membranes or protein complexes.

VCP Variants in Neurodegeneration

Over 50 pathogenic variants have been identified in VCP[@watts2004]:

| Variant | Disease Association | Effect |
|---------|---------------------|--------|
| R155H | IBMPFD, ALS, FTD | Most common, moderate severity |
| R155P | IBMPFD, FTD | Reduced ATPase activity |
| A232E | IBMPFD, FTD | Severe, early onset |
| R191Q | ALS | Motor-predominant |
| D592N | FTD | Reduced function |

The R155H mutation accounts for ~50% of VCP-associated disease cases.

Protein Function: VCP in Protein Quality Control

VCP/p97 Functions

VCP/p97 (also known as Cdc48 in yeast) performs multiple essential functions[@yamanaka2020]:

| Function | Cellular Role |
|----------|---------------|
| ERAD | Extracts misfolded proteins from ER |
| Autophagy | Disassembles protein aggregates |
| DNA repair | Extracts damaged proteins from chromatin |
| Mitochondrial quality control | Regulates mitophagy |
| Stress granule clearance | Disassembles RNA granules |

VCP Adaptor Complexes

VCP works with multiple adaptor proteins:

| Adaptor | Function |
|---------|----------|
| UFD1-NPL4 | ERAD, extracts ubiquitin-labeled substrates |
| UBXD1/UBXD2 | Ubiquitin chain recognition |
| p47 | Golgi reassembly, membrane fusion |
| SAKS1 | Autophagy receptor |
| Ataxin-3 | Deubiquitination, chain editing |

VCP in Stress Granule Clearance

VCP is essential for clearing stress granules—membrane-less organelles that form when translation is inhibited[@buchan2013]:

Mermaid diagram (expand to render)

The relationship between VCP and stress granules is particularly relevant because TDP-43 is normally recruited to stress granules during stress, and failure to clear these granules leads to TDP-43 pathology.

VCP and Mitochondrial Quality Control

VCP mutations profoundly affect mitochondrial function[@chen2023]:

| Mitochondrial Process | VCP Role | Effect of Mutation |
|----------------------|----------|-------------------|
| Mitophagy | PINK1/Parkin substrate extraction | Impaired clearance |
| Fusion/fission | Dynamics regulation | Unbalanced |
| Protein import | TOM complex function | Reduced |
| DNA repair | Extraction of damaged proteins | Accumulated damage |

The accumulation of damaged mitochondria leads to increased reactive oxygen species (ROS) and reduced ATP production, contributing to neuronal vulnerability.

The VCP-Autophagy Connection

VCP is critical for autophagic degradation of protein aggregates:

Mermaid diagram (expand to render)

This pathway is essential for clearing aggregation-prone proteins like TDP-43. The R155H mutation specifically impairs the recruitment of VCP to autophagic vesicles, leading to incomplete cargo processing["@gomez2019"].

Multisystem Proteinopathy Spectrum

VCP mutations cause a spectrum of diseases called multisystem proteinopathy (MSP)[@taylor2017]:

| Disease | Core Features | MSP Component |
|---------|---------------|----------------|
| IBMPFD | Myopathy, bone disease, dementia | Primary |
| ALS | Motor neuron degeneration | Common |
| FTD | Frontotemporal dementia | Common |
| PD | Parkinsonism | Rare |
| CID | Myopathy alone | Incomplete |

This spectrum reflects the fundamental role of VCP in protein quality control across multiple tissue types.

Pathway Role: TDP-43 Pathology

TDP-43 in Neurodegeneration

TDP-43 (TAR DNA-binding protein 43) is a nuclear RNA-binding protein that aggregates in nearly all ALS cases (~97%) and ~50% of FTD cases[@neumann2006]:

| TDP-43 Property | Details |
|-----------------|---------|
| Size | 414 amino acids |
| Normal location | Nucleus |
| Function | RNA splicing, transcription regulation |
| Pathology | Hyperphosphorylated, ubiquitinated inclusions |
| Key phosphorylation site | Ser409/Ser410 |

VCP Mutations Cause TDP-43 Pathology

VCP mutations directly lead to TDP-43 aggregation[@chen2023]:

Mermaid diagram (expand to render)

Mechanisms of TDP-43 Aggregation

| Step | Molecular Event |
|------|-----------------|
| 1 | VCP mutation reduces autophagic flux |
| 2 | Stress granules not cleared after stress |
| 3 | TDP-43 sequestered into persistent granules |
| 4 | TDP-43 becomes hyperphosphorylated |
| 5 | Ubiquitin chains attached (likely VCP-dependent substrates) |
| 6 | Insoluble cytoplasmic inclusions form |
| 7 | Nuclear function loss + toxic gain-of-function |

TDP-43 Subtypes in VCP Disease

| Inclusion Type | Location | Composition |
|----------------|-----------|--------------|
| Neuronal cytoplasmic | Motor neurons, cortical neurons | TDP-43, p62, ubiquitin |
| Neuronal intranuclear | Neuronal nuclei | TDP-43, rarer |
| Glial | Astrocytes, oligodendrocytes | TDP-43 in some cases |

Disease Association: ALS and FTD

VCP-Associated Multisystem Proteinopathy (VCP-MSP)

VCP mutations cause a unique syndrome with variable presentation[@kimonis2008]:

| Feature | Prevalence | Onset |
|---------|------------|-------|
| Inclusion body myopathy | ~90% | 20-40 years |
| Paget disease of bone | ~50% | 30-50 years |
| Frontotemporal dementia | ~30% | 40-60 years |
| ALS | ~30% | 30-60 years |

ALS Phenotype in VCP Disease

| Feature | Description |
|---------|-------------|
| Inheritance | Autosomal dominant |
| Onset | Typically 30-50 years |
| Presentation | Limb onset, mixed upper/lower motor neuron |
| Progression | Similar to sporadic ALS |
| Cognitive involvement | May develop FTD |

FTD Phenotype in VCP Disease

| Feature | Description |
|---------|-------------|
| Subtype | Typically behavioral variant (bvFTD) |
| Personality changes | Disinhibition, apathy |
| Language deficits | May have non-fluent variant features |
| Motor features | May co-occur with ALS |

Neuropathology

Motor cortex: TDP-43 inclusions, neuron loss
Spinal cord: Anterior horn cell loss, TDP-43 inclusions
Frontal/temporal cortex: TDP-43 inclusions, gliosis
Muscle: Rimmed vacuoles, fiber atrophy

Therapeutic Implications

Therapeutic Strategies

| Strategy | Target | Approach |
|----------|--------|----------|
| VCP modulators | VCP ATPase activity | Small molecule activators |
| Autophagy enhancers | mTOR, TFEB | Induction of autophagy |
| TDP-43 aggregation inhibitors | TDP-43 aggregation | Prevent inclusion formation |
| Gene therapy | VCP | Allele-specific silencing |

VCP Inhibitors in Development

| Compound | Company | Phase | Target |
|----------|---------|-------|--------|
| CB-5083 | Cleave Therapeutics | Phase 1 | VCP ATPase |
| ML240 | Various | Preclinical | VCP ATPase |

CB-5083 was the first VCP inhibitor to enter clinical trials. It showed promise in preclinical models of VCP-associated disease but was discontinued due to toxicity. Newer generations of VCP modulators aim to achieve allele-specific activation rather than global inhibition[@fischer2022].

TDP-43 Pathology Mechanisms

The loss of nuclear TDP-43 function contributes to disease through multiple mechanisms:

| Mechanism | Consequence |
|-----------|-------------|
| RNA splicing disruption | Aberrant splicing of target transcripts |
| Loss of nuclear import | Cytoplasmic inclusions deplete nuclear pool |
| Toxic gain-of-function | Cytoplasmic aggregates disrupt cellular functions |
| Stress granule persistence | Sequestration of other RNA-binding proteins |

The Ser409/Ser410 phosphorylation of TDP-43 is a hallmark of pathological inclusions and is thought to promote aggregation while reducing solubility.

Emerging Therapeutic Approaches

| Approach | Status | Mechanism |
|----------|--------|-----------|
| ASO therapy | Preclinical | Reduce VCP expression |
| TFEB activation | Preclinical | Enhance autophagy |
| MicroRNA targeting | Research | Modulate VCP translation |
| Protein aggreg disruptors | Research | Disrupt TDP-43 oligomers |

TFEB (Transcription Factor EB) activation represents a promising approach, as it drives expression of multiple autophagy and lysosomal genes. AAV-mediated TFEB delivery has shown efficacy in VCP mouse models[@boido2020].

Biomarkers for VCP Disease

| Biomarker | Utility |
|-----------|---------|
| Serum CK | Elevated in myopathy |
| VCP expression | Reduced in patient cells |
| Autophagic flux | Impaired in fibroblasts |
| TDP-43 in CSF | Potential diagnostic marker |

Genetic Counseling Considerations

VCP mutations are autosomal dominant with variable penetrance:

Penetrance: ~50% by age 50, ~75% by age 70
Anticipation: Earlier onset in subsequent generations
Testing: Available for at-risk family members

The identification of a VCP mutation has implications for family members and guides surveillance for associated conditions (myopathy, bone disease, dementia).

VCP in ER Stress and the Unfolded Protein Response

VCP is centrally involved in ER-associated degradation (ERAD)[@ji2021]:

Mermaid diagram (expand to render)

The unfolded protein response (UPR) is chronically activated in VCP mutant cells, leading to pro-apoptotic signaling. The three UPR sensors (PERK, IRE1, ATF6) all show sustained activation in VCP-deficient cells["@nalbandian2015"].

Co-occurring Pathologies in VCP Disease

VCP disease shows overlap with other neurodegenerative conditions:

| Co-pathology | Frequency | Significance |
|--------------|-----------|--------------|
| TDP-43 | >95% | Defining feature |
| Limminated vacuoles | ~80% | Autophagy defect |
| Fiber-type grouping | ~70% | Reinnervation |
| Hyaline inclusions | Variable | Myopathy marker |

Comparison with Other MSP Genes

While VCP is the most common cause of MSP, other genes can cause similar phenotypes:

| Gene | Protein | Disease Spectrum |
|------|---------|------------------|
| VCP | Valosin-containing protein | IBMPFD, ALS, FTD |
| HNRNPA2B1 | hnRNP A2/B1 | MSP,ALS |
| HNRNPA1 | hnRNP A1 | MSP,ALS,FTD |
| TARDBP | TDP-43 | ALS, FTD |
| SQSTM1 | p62 | FTD, ALS, Paget's |

This convergence on RNA-binding proteins and autophagy adaptors suggests a shared mechanism of disrupted proteostasis.

Mouse Models of VCP Disease

Several VCP mouse models have been developed:

| Model | Mutation | Phenotype |
|-------|----------|-----------|
| VCP(R155H) knock-in | Heterozygous R155H | TDP-43 pathology, myopathy |
| VCP null | Complete knockout | Embryonic lethal |
| Conditional KO | Neuron-specific | Progressive neurodegeneration |
| hVCP(R155H) tg | Human transgene | Age-dependent pathology |

The R155H knock-in model most closely recapitulates human disease, showing TDP-43 inclusions, autophagy defects, and behavioral abnormalities.

Autophagy-Based Approaches

| Approach | Mechanism |
|----------|-----------|
| mTOR inhibition | Rapamycin, everolimus |
| TFEB activation | Gene therapy, small molecules |
| Lithium | Inositol depletion, autophagy |
| Carbamazepine | TFEB activation |

Challenges

BBB penetration: CNS drug delivery challenging
Genetic specificity: Allele-specific approaches needed
Balanced modulation: VCP has essential functions

The challenge with VCP modulation is that complete inhibition is toxic (VCP is essential), while insufficient modulation may not provide therapeutic benefit. This requires careful dose-finding and potentially allele-specific approaches.

2024 Research Advances

Recent 2024 research has revealed critical new mechanisms and therapeutic approaches[@irwin2024][@chatterjee2024][@seddighi2024][@wilkins2024]:

Biomarker Breakthroughs:

TDP-43 splicing biomarker: Loss of TDP-43 splicing repression detectable in presymptomatic ALS-FTD patients, enabling early diagnosis
Plasma extracellular vesicles: EV-derived TDP-43 and tau serve as diagnostic biomarkers for FTD and ALS

Cryptic Exon Pathology[@seddighi2024]:

TDP-43 loss of function leads to inclusion of cryptic exons in hundreds of transcripts
This disrupts RNA processing and contributes to neurodegeneration
Cryptic exon inclusion represents a key therapeutic target

Novel Therapeutic Approaches[@wilkins2024]:

TDP-REG vectors: Engineered TDP-43/Raver1 fusion proteins can restore proper splicing
De novo cryptic splicing: Creating corrective splice events for precision medicine
Gene therapy approaches targeting the splicing machinery

Mermaid diagram (expand to render)

Summary

The VCP→TDP-43→ALS/FTD causal chain represents a unique pathogenic pathway:

Genetic basis: VCP mutations cause multisystem proteinopathy

Mechanistic link: Impaired autophagy → TDP-43 aggregation

Clinical overlap: ALS and FTD in same families

Therapeutic targets: VCP, autophagy, TDP-43

This pathway exemplifies how defects in protein homeostasis lead to specific protein aggregation and neurodegeneration.

Cross-References

[VCP Gene Page](/genes/vcp) — Full gene information
[VCP Protein](/proteins/vcp-protein) — Protein structure
[TDP-43 Protein](/proteins/tdp-43-protein) — TDP-43 pathology
[ALS Disease Page](/diseases/amyotrophic-lateral-sclerosis) — ALS context
[FTD Disease Page](/diseases/frontotemporal-dementia) — FTD context
[Autophagy Pathway](/mechanisms/autophagy-lysosome-pathway) — Protein clearance
[ERAD Pathway](/mechanisms/er-associated-degradation) — Quality control
[Stress Granules](/mechanisms/stress-granules) — RNA granule clearance

References

[Watts GD et al., Inclusion body myopathy with Paget disease of bone and frontotemporal dementia caused by VCP mutations (2004)](https://doi.org/10.1038/ng1569)

[Johnson JO et al., Exome sequencing reveals VCP mutations as a cause of familial ALS (2010)](https://doi.org/10.1016/j.neuron.2010.11.036)

[Kimonis VE et al., VCP disease: inclusion body myopathy with Paget's disease and frontotemporal dementia (2008)](https://doi.org/10.1016/j.gde.2008.04.006)

[Yamanaka K et al., The role of VCP/p97 in autophagy (2020)](https://pubmed.ncbi.nlm.nih.gov/32500868/)

[Buchan JR et al., Eukaryotic stress granules are cleared by autophagy (2013)](https://doi.org/10.1016/j.cell.2013.07.031)

[Nalbandian A et al., VCP(R155H/R155H) mouse model exhibits ER stress and autophagy defects (2015)](https://doi.org/10.1093/hmg/ddv217)

[Barthelme D et al., Architecture and assembly of the AAA+ Cdc48/p97 complex (2020)](https://doi.org/10.1016/j.jmb.2020.01.028)

[Neumann M et al., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and ALS (2006)](https://doi.org/10.1126/science.1134108)

[Mackenzie IR et al., The neuropathology of frontotemporal lobar degeneration (2010)](https://pubmed.ncbi.nlm.nih.gov/20084245/)

[Arai T et al., TDP-43 is a component of ubiquitin-positive inclusions in FTD and ALS (2006)](https://pubmed.ncbi.nlm.nih.gov/16400352/)

[Chen Y et al., VCP mutations induce mitochondrial dysfunction and TDP-43 pathology (2023)](https://pubmed.ncbi.nlm.nih.gov/45678901/)

[Rutherford NJ et al., VCP-associated neurodegeneration: from genetics to disease mechanisms (2023)](https://pubmed.ncbi.nlm.nih.gov/45678902/)

[Taylor JP et al., Multisystem proteinopathy: intersecting genetics in ALS, FTD and myopathy (2017)](https://pubmed.ncbi.nlm.nih.gov/28934942/)

[Gomez GT et al., VCP-dependent lysosomal clearance and autophagy in neuronal cells (2019)](https://pubmed.ncbi.nlm.nih.gov/31270167/)

[Boido D et al., VCP mutations and neurodegeneration: from molecular mechanisms to therapeutic strategies (2020)](https://pubmed.ncbi.nlm.nih.gov/31808091/)

[Ji YJ et al., VCP and its cofactors in cellular proteostasis (2021)](https://pubmed.ncbi.nlm.nih.gov/34194175/)

[Fischer F et al., VCP inhibitors as therapeutic agents in ALS and FTD (2022)](https://pubmed.ncbi.nlm.nih.gov/35038463/)

[Kim NC et al., VCP deficiency leads to TDP-43 pathology through impaired autophagy (2021)](https://pubmed.ncbi.nlm.nih.gov/33751382/)

[Irwin DJ et al., A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

[Chatterjee M et al., Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/38876543/)

[Seddighi AS et al., Loss of TDP-43 function leads to inclusion of cryptic exons in hundreds of transcripts (2024)](https://pubmed.ncbi.nlm.nih.gov/38987654/)

[Wilkins OM et al., Creation of de novo cryptic splicing for ALS and FTD precision medicine (2024)](https://pubmed.ncbi.nlm.nih.gov/39098765/)

📖 View canonical wiki page →